



IMUGENE

Developing Cancer Immunotherapies

ASX: IMU

DEVELOPING CANCER IMMUNOTHERAPIES

May, 2024



DISCLAIMER

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change
6. International offer restrictions – This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

INVESTMENT HIGHLIGHTS

MARKET CAPITALISATION AS OF
29 APRIL 2024

A\$593M



CASH AS OF
31 MARCH 2024

A\$114.1M



4 PLATFORM TECHNOLOGIES



Allo CAR T Cell Therapy
CF33 Oncolytic Virus
onCARlytics
B Cell Immunotherapy



Azer-Cel Research Center in
Durham, North Carolina

DISEASE AREAS

Blood cancers (DLBCL)
Breast (TNBC)
Lung (NSCLC)
Gastric
Gastroesophageal
Colorectal (CRC)
Melanoma
Head and Neck
Hepatocellular
Pancreatic
Glioblastoma (GBM)
Bile Tract Cancer



4 CLINICAL STUDIES

azer-cel Ph1b DLBCL (FDA IND)
VAXINIA: Ph1 Solid Tumours (FDA IND)
onCARlytics: Ph1 Solid Tumours (FDA IND)
PD1-Vaxx: Ph2 neoPOLEM

LONG-LIFE PATENT PORTFOLIO



IMUGENE CLINICAL EXECUTIVE TEAM



Over 150 years of combined experience in Clinical Development
13 FDA Approved Drugs to market





AZER-CEL CD19 ALLOGENEIC CAR T CELL THERAPY



THE FUTURE OF CELL THERAPY IS OFF THE SHELF (ALLOGENEIC) CAR T

Patients shouldn't have to wait for treatment



- Auto CAR Ts are made from the patient's own T-cells cells. Limited patient access (highly personalized)
- Long and complex manufacturing process and wait time (requires leukapheresis* and often extra chemotherapy treatment until cells are ready)
- High manufacturing costs
- Variable potency due to health of patients own T cells

- Allo CAR Ts are made from a universal donor. Broad patient access (multiple patients from a single batch)
- Can be mass produced, available on demand and off-the-shelf immediately (no leukapheresis* and no bridging treatment required). **Ready when you need them.**
- More efficient and cost-effective manufacturing
- Healthy donor cells engineered for potency and persistence

AZER-CEL HAS MEANINGFUL CLINICAL ACTIVITY IN B CELL MALIGNANCIES

84 patients treated with azer-cel

61

Non-Hodgkin lymphoma (NHL)
Patients

58% ORR¹

41% CR²



23

B-Cell lymphoblastic
leukaemia (B-ALL) Patients

61% ORR

61% CR/CRi

All Doses / All LD* Regimens

1. ORR – Overall Response Rate

2. CR – Complete Response


*lymphodepletion

Note: Based on Patients Evaluable for Efficacy

AZER-CEL HAS THE POTENTIAL TO BE A NEW STANDARD OF CARE

High response rates and durability

84 blood cancer patients treated with azer-cel: 61 patients with Non-Hodgkin lymphoma (NHL); 23 patients with B-Cell acute lymphoblastic leukaemia (B-ALL)



Note: Based on Patients Evaluable for Efficacy

¹N=11 patients evaluable for > 6 months duration on response, 6 durable responders past 6 months or longer with 431 (> 1 year) median days on response; DoR measured from D0

*lymphodepletion


DIFFUSE LARGE B-CELL LYMPHOMA IS AN AGGRESSIVE TYPE OF NON-HODGKIN LYMPHOMA



- B-cells become cancerous and grow uncontrollably
- Most common type of non-Hodgkin lymphoma (80,500 cases/year)
- Most common in people over 50
- Fast growing and needs rapid treatment
- Relapsed/refractory DLBCL has a high unmet medical need

HOW IS DLBCL TREATED TODAY?

~30,000 New Cases in the U.S. Annually (2020 – SEER)



¹Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride (Hydroxydaunomycin), Vincristine Sulfate (Oncovin), Prednisone

²COLUMVI® received conditional accelerated marketing authorisation in 2023 for 3L+ DLBCL

CD19 AUTOLOGOUS CAR T RELAPSE MARKET IS LARGE AND GROWING



~85%

of patients continue to express CD19 the target of azer-cel

In our prospective data, patients continue to have antigen positive disease¹

60-65%

of patients currently treated with autologous CD19 CAR T will relapse²

By 2025

Global CAR T relapse patient pool is expected to grow ~4x as autologous CAR T drugs become the SOC

Estimate total Global G8 markets to be ~18k patients per year³

Azer-cel has the potential to be a blockbuster drug in DLBCL CAR T relapsed patients

Note: Retrospective Literature states that 12-28% of patients have antigen negative relapse (CD19-)

1. Precision Internal Clinical Data;
2. Estimated from ZUMA 1 and ZUMA 7 EFS rates;
3. G8 includes US, Japan, Canada and EU5 assuming equal access to CAR T therapies; market research, CancerMPac

PHASE 2 TRIAL ASSUMPTIONS (POTENTIAL REGISTRATIONAL/TO MARKET)

Potential registrational trial (FDA approval) to start upon completion of the Phase 1B trial. Dependent on acceptable CR rate and durability of CR

Population: Relapse after auto-CART in DLBCL patients

Positive FDA guidance on the potential registrational trial

~35+ sites in the U.S.: Phase 1B trial currently conducted at Moffit, COH, Karmanos, U Minnesota, Rhode Island, Cornell, Columbia

Drug product for Phase 1B confirmatory trial completed

Drug material manufactured in North Carolina by Kincell Bio



IMUGENE AND KINCELL BIO PARTNERSHIP

Kincell Bio acquired Imugene's North Carolina manufacturing facility

- Imugene retains rights to azer-cel
- Imugene will receive up to \$6M USD in upfront and milestone-driven payments over 3 years
- Imugene will recognize \$32M USD in staff cost reductions, manufacturing efficiencies and overhead savings over the next 3 years
- Kincell will manufacture Imugene's azer-cel clinical trial supply



kincell




CF33 Oncolytic Virus
IMUGENE

CF33 ONCOLYTIC VIRUS



CF33 CAN INFECT AND SELECTIVELY KILL TUMOR CELLS



Engineering enhancements

- Infect and kill only cancer cells
- Carry payloads to increase killing

Multiple ways to kill cancer cells

- Direct killing
- Activation of immune cells to kill cancer cells
- Priming the tumour environment to enhance immune response¹

Precedent for approval

- Tvec approved in the United States for skin cancer (2015)
- Oncorine approved in China for head and neck cancer (2005)
- Delytact approved in Japan for brain cancer (2021)

OUR PHASE 1 MAST STUDY HAS ENROLLED WELL



Dose Administration (Parallel Groups)

n=52-100 patients




**Intratumoural (IT)
Administration**
Metastatic and
Advanced Solid
Tumours




**Intravenous (IV)
Administration**
Metastatic and
Advanced Solid
Tumours

Site Location: USA,
AUS

VAXINIA Monotherapy Dose Escalation



VAXINIA + Pembrolizumab Combination Dose Escalation



Cohort Expansion

Expansion Cohorts
(N=10)

**Tumour Types of
Interest:**
i.e. Cholangiocarcinoma
(IT will occur first)

PHASE 1 MAST (METASTATIC ADVANCED SOLID TUMOURS) TRIAL - ENCOURAGING EARLY SIGNALS



- The Phase I trial treats advanced cancer patients intravenously (IV) or intratumorally (IT) with CF33-hNIS (VAXINIA) alone, or in combination with pembrolizumab in multiple solid cancers
- 47 heavily pre-treated patients have been dosed to date (24 April 2024*), of which 40 patients have been evaluated, meaning they received at least their first scan at day 42
- Nearly half of the evaluable patients (**48%**) have remained on treatment for more than 3 months, representing significant disease control; 3 monotherapy patients have remained on treatment for over 200 days
- During dose escalation, 1 patient with bile tract cancer who failed 3 prior treatments achieved a complete response (CR), which has continued for almost 1.5 years (532 days); 2 patients with melanoma achieved partial responses (PRs), and 17 patients achieved stable disease (SD) while in the trial
- The MAST trial continues to advance and has progressed to higher dose cohorts
- Bile tract cancer expansion trial opened and is expected to enroll approximately 10 patients; preliminary early data is expected in the second half 2024
- The trial is recruiting across 8 sites in the US and 2 sites in Australia
- The company received US FDA Fast Track Designation for bile tract cancer in November 2023, which allows for faster review



HIGHLANDS
ONCOLOGY




Cancer Center



*Preliminary enrollment update; data and number of evaluable patients subject to change with full statistical analysis


TURNING COLD TUMOURS HOT

Complete Remission after Pseudoprogression (immune activity) in a Monotherapy patient with a cold tumour (bile tract cancer)



Baseline scan
Start of the Trial

Second scan
Pseudoprogression
(Tumour looks to have grown due to immune activity)



Third scan
Decreased size

Fourth scan
Complete Remission


This patient had received 3 prior lines of chemotherapy and was PD-L1 negative with no response prior to CF33

ONCARLYTICS FOR SOLID TUMORS




VARIETY OF APPROVED CD19 DRUGS ONLY FOR BLOOD CANCERS

- Many blood cancers such as leukemia and lymphoma have a common protein, called CD19, on the surface of their cells
 - When you modify a patient's T Cells to "see" the CD19 signal, the T cell becomes laser focused on only targeting CD19, and ignores the patient's healthy cells
- Solid cancers like breast, lung, gastric, colon, etc. don't have a common target such as CD19, on their cell surface
 - The holy grail in CAR T therapy is to find a CAR T which works in solid tumours (90% of cancer market)
 - Imugene's onCARlytics technology seeks to overcome this challenge in solid cancers



MECHANISM OF ACTION: HOW DOES IT WORK?




onCARlytics makes solid tumours “seen” by CD19 targeting therapies

1. OnCARlytics infects Tumour cells
2. Virus replication and production of CF33-CD19 on the cell surface enabling CD19 cell targeting
3. Tumour cell lysis leads to viral particle release and the combination promotes endogenous immune cell recruitment to Tumours
4. Released viral particles re-initiate virus infection of surrounding Tumour cells.

PHASE 1 OASIS TRIAL

- Phase 1 trial designed to treat with onCARlytics (CF33-CD19) alone, or in combination with Blinatumomab (bispecific antibody targeting CD19) and either dosed IV or IT in metastatic advanced patients across multiple solid tumours
- First IT and IV patient dosed (ovarian cancer) at City of Hope in October 2023 and February 2024 respectively
- Many CD19 approved drugs, which could become preferred partners to combine with onCARlytics (~90% of cancer)
- The Cohort Review Committee (CRC) observed no safety issues in the onCARlytics monotherapy lead-in trial
- Combination with OnCARlytics and Blinatumomab now open
- Phase 1 planned for ~10 sites in the U.S. in ~40–45 patients with advanced solid tumours
- Preliminary early combination data are expected in the 4Q 2024

Combination treatment for solid tumours



VARIETY OF APPROVED THERAPIES AVAILABLE FOR COMBINATION WITH ONCARLYTICS

onCARlytics can become the preferred partner for CD19 therapies in solid tumours (~90% of cancer market)


Combination Opportunities

- Azer-cel (allo CD19 CAR T)
- Autologous CD19 CARTs
- Bispecific antibodies targeting CD19
- Antibody-drug Conjugates (ADC)
- Monoclonal Antibodies (MABs)


COMPANY	FIRST FDA APPROVAL	TARGET	APPROVED CANCERS
 KYMRIA [®] (tisagenlecleucel) dispersion for IV infusion  NOVARTIS	2017	CD19 Auto CAR T	B-ALL, DLBCL
 YESCARTA [®] (axicabtagene ciloleucel) dispersion for IV infusion  Kite A GILEAD Company	2017	CD19 Auto CAR T	DLBCL, R/R FL
 TECARTUS [®] (brexucabtagene autoleucel) dispersion for IV infusion  Kite A GILEAD Company	2020	CD19 Auto CAR T	R/R MCL
 Breyanzi [®] (lisocabtagene maraleucel) dispersion for IV infusion  Bristol Myers Squibb	2021	CD19 Auto CAR T	DLBCL
 MONJUVI [®] tafasitamab-cxix 200mg for injection, for intravenous use  morphosys	2020	CD19 Monoclonal Antibodies (MABs)	DLBCL
 Uplizna [®] inebilizumab-cdon  HORIZON	2020	CD19 MABs	NMOSD
 BLINCYTO [®] (blinatumomab) for injection, 25 mg single dose vial  AMGEN	2014	CD19-CD3 Bispecific MABs	ALL
 Zynlonta [®] loncastuximab tesine-lpyl for injection, for intravenous use • 10mg  ADC THERAPEUTICS	2021	CD19 Antibody-drug conjugate (ADC)	B-Cell Lymphoma

AZER-CEL OFFERS ONCARLYTICS AN IN-HOUSE COMBINATION APPROACH FOR SOLID TUMOURS

- Azer-cel in combination with onCARlytics demonstrated sustained, robust activity against multiple tumour types
- 100% killing of Triple Negative Breast Cancer (468P) and Gastric (SNU16) Cancer lines was observed compared to controls at 72 hours



Combination treatment for solid tumours



B-CELL IMMUNOTHERAPIES



PD1-VAXX PH2 NEOPOLEM NEOADJUVANT (PRE-SURGERY) IST IN MSI-HIGH COLORECTAL CANCER (CRC)

Site Locations:
AUS & UK

Patient: n= 44

**Inoperable,
MSI-High
CRC**

Sites in feasibility:
- 6 in AUS
- 4 in UK

Neoadjuvant Treatment

Days 1 - 29



3 doses PD1-Vaxx

Surgery

Within 3 weeks of last dose



Follow Up

Outcomes:

- Safety
- Major Pathological Response
- Objective Response Rate
- Disease Free Survival
- Overall Survival

First Patient Enrolled Planned: 1H 2024

Objectives: Tumour response, safety, immunogenicity

KEY CATALYSTS FOR THE NEXT 12-18 MONTHS

H1 2024

- **PD1-VAXX**: FPI Neo-POLEM (Phase 2 MSI-H CRC)
- **ONCARLYTICS**: FPI IT and IV Combo Cohort 2
- **VAXINIA**: IT Mono Bile Tract Expansion Open

H2 2024

- **VAXINIA**: IT Expansion Open other indication
- **AZER-CEL**: Preliminary early DLBCL Phase 1b data update
- **ONCARLYTICS**: Early IT and/or IV Combo data

2025

- **AZER-CEL**: DLBCL Phase 1b data updates
- **AZER-CEL**: Target regulatory meeting with FDA
- **ONCARLYTICS** + **AZER-CEL**: FDA IND and FPI in solid tumours
- **AZER-CEL**: expansion into additional blood cancers (Phase 1 Expansion Cohort)
- **VAXINIA**: Phase 2 FPI
- **VAXINIA**: Phase 2 Interim Data Read out
- **VAXINIA**: IP & IA Phase 1 FPIs
- **ONCARLYTICS**: Data update and trial expansion
- **PD1-VAXX**: NeoPOLEM (Phase 2 MSI-H CRC) update

Key:

FPI, First Patient In, **MSI-H**: Microsatellite Instability High, **Combo**: Combination Therapy **Mono**: Monotherapy, **DLBCL**: Diffuse Large B-Cell Lymphoma, **IA**: Intra-arterial, **IP**: Intraperitoneal, **IT**: Intratumoural, **IV**: Intravenous

WHY IMUGENE?

Value Proposition for Investors



Advanced Portfolio
with multiple
shots on goal.
**Leader in developing
allogeneic CAR T cell
therapy**



Experienced management
team with over 150 years
of combined experience in
drug development &
approvals



Ongoing clinical trials
in blood cancer and
diverse solid tumours
with multiple value
inflection points



Robust cash runway;
prudent use of funds to
protect and conserve
cash resources with
prioritized programs

INVESTMENT HIGHLIGHTS

MARKET CAPITALISATION AS OF
29 APRIL 2024

A\$593M



CASH AS OF
31 MARCH 2024

A\$114.1M



4 PLATFORM TECHNOLOGIES



Allo CAR T Cell Therapy
CF33 Oncolytic Virus
onCARlytics
B Cell Immunotherapy



Azer-Cel Research Center in
Durham, North Carolina

DISEASE AREAS

Blood cancers (DLBCL)
Breast (TNBC)
Lung (NSCLC)
Gastric
Gastroesophageal
Colorectal (CRC)
Melanoma
Head and Neck
Hepatocellular
Pancreatic
Glioblastoma (GBM)
Bile Tract Cancer



4 CLINICAL STUDIES

azer-cel Ph1b DLBCL (FDA IND)
VAXINIA: Ph1 Solid Tumours (FDA IND)
onCARlytics: Ph1 Solid Tumours (FDA IND)
PD1-Vaxx: Ph2 neoPOLEM

LONG-LIFE PATENT PORTFOLIO





IMUGENE

Developing Cancer Immunotherapies

ASX:IMU

shareholderenquiries@imugene.com
imugene.com

